|
Mar 14
|
Better Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq
|
|
Mar 5
|
Better Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health Centers
|
|
Mar 4
|
Better Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
|
|
Jan 18
|
David Perry Bought 8.6% More Shares In Better Therapeutics
|
|
Jan 17
|
Better Therapeutics Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx is More Effective and Less Costly than Standard of Care Alone
|
|
Jan 4
|
Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States
|
|
Jan 3
|
Better Therapeutics Insiders Added US$6.57m Of Stock To Their Holdings
|
|
Nov 28
|
Better Therapeutics Strengthens Financial Position Through Amendment to Debt Facility and Implementation of Cost Reductions
|
|
Nov 14
|
Frost & Sullivan Honors Better Therapeutics with the 2023 Technology Innovation Leadership Award
|
|
Nov 8
|
Better Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 09, 2023
|
|
Aug 9
|
Better Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
|